{rfName}
Bi

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Pérez De Oteyza JAuthor
Share
Publications
>
Article

Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia.

Publicated to:Medicine International. 2 (2): 7- - 2022-01-01 2(2), DOI: 10.3892/mi.2022.32

Authors: Martínez-López J; Montesinos P; López-Muñoz N; Ayala R; Martínez-Sánchez P; Gorrochategui J; Rojas-Rudilla JL; Primo D; Bergua-Burgues JM; Calbacho M; Acuña-Cruz E; Pérez-Simón JA; De La Fuente A; Pérez De Oteyza J; Rodriguez-Veiga R; Pina JS; Boluda B; Cano I; Paciello Coronel ML; Ballesteros J

Affiliations

Bioinformatics, Vivia Biotech, 28760 Madrid, Spain. - Author
Department of Hematology and Hemotherapy, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain. - Author
Department of Hematology, 12 de Octubre Hospital, 28041 Madrid, Spain. - Author
Department of Hematology, 12 de Octubre Hospital, Instituto de Investigación Hospital 12 de Octubre (i+12), Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, 28041 Madrid, Spain. - Author
Department of Hematology, HM Sanchinarro University Hospital, School of Medicine, University CEU San Pablo, 28050 Madrid, Spain. - Author
Department of Hematology, MD Anderson Cancer Center, 28033 Madrid, Spain. - Author
Department of Hematology, San Pedro de Alcántara Hospital, 10003 Cáceres, Spain. - Author
Department of Hematology, Virgen del Rocio University Hospital, Institute of Biomedicine of Sevilla (IBIS/CSIC, CIBERONC), University of Sevilla, 41013 Sevilla, Spain. - Author
Vivia Biotech, 28760 Madrid, Spain. - Author
VP Science, Vivia Biotech, 28760 Madrid, Spain. - Author
See more

Abstract

Keywords
Ex vivo sensitivity testMaximum tolerated doseOpb-111077Relapsed/refractory acute myeloid leukemiaStat3

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-05-23:

  • Europe PMC: 1
  • OpenCitations: 1
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-23:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 1 (PlumX).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: China.